CorMedix Inc Stock Prediction and Forecast [CRMD]

AI-generated source summary

CorMedix (CRMD) stock is analyzed with a focus on its potential as a buy. The analysis begins with a system identification of CRMD as a buy candidate, scoring 4.38 as of October 20, 2025. Short-term, CRMD is in a broad, declining trend with a potential 6.73% decline over three months and returns between -22.93% and +9.43%. Longer-term the 12-month analysis projects a 17.61% change, returns between -29.53% and +68.58%. On the last trading day the price closed at $12.16, which is a rise of 19.45% on the last trading day. The low/high for this day was $11.22 and $12.56, and had fluctuations of 11.97%. Based on the last 100 insider trades we have determined an insider power with ratio of 24.844. A stop loss is advised at $11.69.

AI-generated summary based on the source content.

Evidence and evaluation progress

1. Original source published

   21 Oct 2025, 04:09 UTC

   The analyst published the original source item.

2. First prediction resolved

   21 Oct 2025, 13:30 UTC

   The first evaluable outcome in this case reached a terminal result.

3. Case evaluation completed

   21 Oct 2025, 13:30 UTC

   All evaluable predictions in this case reached terminal outcomes.

4. Source recorded by Tahlil Plus

   18 May 2026, 20:23 UTC

   The public source was preserved as the evidence record for this case.

5. Market predictions extracted

   18 May 2026, 20:47 UTC

   1 eligible signal linked to this case.

6. Outcome tracking started

   02 Jul 2026, 01:22 UTC

   Tahlil Plus began monitoring the extracted predictions.